Discovery of a urea-based hit compound as a novel inhibitor of transforming growth factor-β type 1 receptor: in silico and in vitro studies

Abstract

An efficient virtual screening pipeline was developed and eighty compounds were screened from a pool of over 17 million molecules based on docking scores and binding free energy. Cpd272 demonstrated moderate inhibitory activity against TGFβR1.